Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting | Business Wire
Articles with Puma Biotechnology
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
PRESS RELEASE PUMA announces Mark Coetzee as Program ...
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Has a Simple Plan to Get Back to Growth | The Motley Fool
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire